

Supplementary materials

Supplementary Table

Table S1. Demographic of PD patients in the study

	Moderate responder (Moderate, n = 5)	Good responder (Good, n = 5)	P
Age (years)	68.2 ± 5.0	66.8 ± 6.7	0.513
Female (n, %)	2 (40.0)	3 (60.0)	0.527
BMI (kg/m ²)	23.5 ± 1.5	24.2 ± 3.9	0.715
UPDRS-III improvement post-dose (%)	28.9 ± 2.3	53.7 ± 7.8	< 0.001
Disease duration (y)	7.6 ± 3.7	9.0 ± 3.2	0.543
Hoehn and Yahr stage	2.2 ± 0.8	2.1 ± 0.4	0.803
MDS-UPDRS Part I score	10.8 ± 6.5	10.4 ± 1.3	0.896
MDS-UPDRS Part II score	15.4 ± 10.4	11.8 ± 5.2	0.507
MDS-UPDRS Part III score	30.8 ± 16.3	35.2 ± 10.7	0.628
MDS-UPDRS Part total score	60.0 ± 34.3	60.0 ± 19.0	0.999
LEDD (mg)	577.5 ± 287.3	582.5 ± 207.2	0.976

Data are presented as mean ± standard deviation or frequency (percentage). Differences between groups were assessed using the chi-square test for categorical data and Mann-Whitney U test for numerical data. BMI, body mass index. MDS-UPDRS, Movement Disorder Society Unified Parkinson's Disease Rating Scale. LEDD, levodopa equivalent daily dosage.

Supplementary Figure




Figure S1. Relative level of gut microbiota between two group. Data are represented as the mean $\pm$ SEM. t-test was used to determine significance. **P < 0.01. ***P < 0.001. Related to Figure 1.